HMC – UBS rates the stock as Sell

UBS observes Home Consortium has outperformed the A-REIT index by 90% since its IPO in 2019. The business has articulated a clear growth strategy, and UBS is impressed by the track record in transitioning to be an asset-light fund manager.

Nevertheless, the broker initiates coverage with a Sell rating and $5.20 target, given the excessively high expectations for asset growth implied by current market pricing. Moreover, this growth is reliant on support from listed equity capital.

Sector: Real Estate.

 

Target price is $5.20.Current Price is $5.84. Difference: ($0.64) – (brackets indicate current price is over target). If HMC meets the UBS target it will return approximately -12% (excluding dividends, fees and charges – negative figures indicate an expected loss).

 

 

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →